logo
CureVac

CureVac

Description

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes.

The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.

CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 600 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

Detailed Information

Number of employees:

100-500

Status:

Public

Business Model:

B2B, B2C

Year founded:

2000

Academia Based:

No

Location

City:

Tֳ¼bingen

State / Province / Region:

Baden-Wֳ¼rttemberg

Postal / Zip Code:

Full Address:

Tübingen, Baden-Württemberg

Our news:

Cooming soon

CureVac Pr posts

Cooming soon